Musculoskeletal disorders in chronic obstructive pulmonary disease

Nele Cielen, Karen Maes, Ghislaine Gayan-Ramirez, Nele Cielen, Karen Maes, Ghislaine Gayan-Ramirez

Abstract

Chronic obstructive pulmonary disease (COPD) is a lung disease characterized by airway obstruction and inflammation but also accompanied by several extrapulmonary consequences, such as skeletal muscle weakness and osteoporosis. Skeletal muscle weakness is of major concern, since it leads to poor functional capacity, impaired health status, increased healthcare utilization, and even mortality, independently of lung function. Osteoporosis leads to fractures and is associated with increased mortality, functional decline, loss of quality of life, and need for institutionalization. Therefore, the presence of the combination of these comorbidities will have a negative impact on daily life in patients with COPD. In this review, we will focus on these two comorbidities, their prevalence in COPD, combined risk factors, and pathogenesis. We will try to prove the clustering of these comorbidities and discuss possible preventive or therapeutic strategies.

Figures

Figure 1
Figure 1
Reduced muscle strength of the quadriceps, pectoralis major, and latissimus dorsi obtained in normal subjects and patients with COPD. All three types of muscles show decreased muscle strength in patients with COPD. *P < 0.005 Reprinted with permission of the American Thoracic Society. Copyright © 2014 American Thoracic Society, official journal of the American Thoracic Society [17].
Figure 2
Figure 2
Cross-sectional area as well as muscle force of thigh muscle was reduced in patients with COPD (b) compared to normal subject (a). Reprinted with permission of the American Thoracic Society. Copyright © 2014 American Thoracic Society, official journal of the American Thoracic Society [17].
Figure 3
Figure 3
Survival of patients with COPD with normal and reduced quadriceps strength. The curves are significantly different P = 0.017 [24].
Figure 4
Figure 4
Bone mineral density in different GOLD stages. The T-score is the difference between the patient's results and the mean results obtained in a young population, expressed in units of standard deviation. Osteoporosis is the condition with a T-score below −2.5; osteopenia is the condition of a T-score between −1 and −2.5. The prevalence of low bone mineral density increases with higher GOLD stage [25].
Figure 5
Figure 5
Several risk factors, such as cigarette smoke, physical inactivity, inflammation and oxidative stress, corticosteroid use, hormonal disturbances, nutritional deficits, and age, lead to the development of skeletal muscle weakness and osteoporosis in healthy individuals, as well as patients with COPD. There are several therapy modalities that can be used to treat or inverse the consequences of these risk factors so that the risk of developing skeletal muscle weakness and osteoporosis can be reduced in patients with COPD.

References

    1. Vestbo J, Hurd SS, Agusti AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. 2013;187(4):347–365.
    1. World Health Statistics. internet Communication, 2013.
    1. Decramer M, Janssens W, Miravitlles M. Chronic obstructive pulmonary disease. 2012;379(9823):1341–1351.
    1. Skeletal muscle dysfunction in chronic obstructive pulmonary disease: a statement of the American Thoracic Society and European Respiratory Society. 1999;159(4):S1–S40.
    1. Seymour JM, Spruit MA, Hopkinson NS, et al. The prevalence of quadriceps weakness in COPD and the relationship with disease severity. 2010;36(1):81–88.
    1. Engelen MPKJ, Schols AMWJ, Does JD, Wouters EFM. Skeletal muscle weakness is associated with wasting of extremity fat-free mass but not with airflow obstruction in patients with chronic obstructive pulmonary disease. 2000;71(3):733–738.
    1. WHO Scientific Group. Prevention and management of osteoporosis: report of a WHO scientific group. internet communication, 2013.
    1. Graat-Verboom L, Wouters EFM, Smeen FWJM, van den Borne BEEM, Lunde R, Spruit MA. Current status of research on osteoporosis in COPD: a systematic review. 2009;34(1):209–218.
    1. Bolton CE, Ionescu AA, Shiels KM, et al. Associated loss of fat-free mass and bone mineral density in chronic obstructive pulmonary disease. 2004;170(12):1286–1293.
    1. de Vries F, van Staa TP, Bracke MSGM, Cooper C, Leufkens HGM, Lammers J-WJ. Severity of obstructive airway disease and risk of osteoporotic fracture. 2005;25(5):879–884.
    1. Kjensli A, Mowinckel P, Ryg MS, Falch JA. Low bone mineral density is related to severity of chronic obstructive pulmonary disease. 2007;40(2):493–497.
    1. Culham EG, Jimenez HAI, King CE. Thoracic kyphosis, rib mobility, and lung volumes in normal women and women with osteoporosis. 1994;19(11):1250–1255.
    1. Schlaich C, Minne HW, Bruckner T, et al. Reduced pulmonary function in patients with spinal osteoporotic fractures. 1998;8(3):261–267.
    1. Myers ER, Wilson SE. Biomechanics of osteoporosis and vertebral fracture. 1997;22(24):25S–31S.
    1. Ferguson GT, Calverley PMA, Anderson JA, et al. Prevalence and progression of osteoporosis in patients with COPD: results from the towards a revolution in COPD health study. 2009;136(6):1456–1465.
    1. Rabinovich RA, Vilaró J. Structural and functional changes of peripheral muscles in chronic obstructive pulmonary disease patients. 2010;16(2):123–133.
    1. Bernard S, Leblanc P, Whittom F, et al. Peripheral muscle weakness in patients with chronic obstructive pulmonary disease. 1998;158(2):629–634.
    1. Singer J, Yelin EH, Katz PP, et al. Respiratory and skeletal muscle strength in chronic obstructive pulmonary disease: impact on exercise capacity and lower extremity function. 2011;31(2):111–119.
    1. Franssen FME, Broekhuizen R, Janssen PP, Wouters EFM, Schols AMWJ. Limb muscle dysfunction in COPD: effects of muscle wasting and exercise training. 2005;37(1):2–9.
    1. Crul T, Spruit MA, Gayan-Ramirez G, et al. Markers of inflammation and disuse in vastus lateralis of chronic obstructive pulmonary disease patients. 2007;37(11):897–904.
    1. Spruit MA, Gosselink R, Troosters T, et al. Muscle force during an acute exacerbation in hospitalised patients with COPD and its relationship with CXCL8 and IGF-I. 2003;58(9):752–756.
    1. Franssen FME, Wouters EFM, Baarends EM, Akkermans MA, Schols AMWJ. Arm mechanical efficiency and arm exercise capacity are relatively preserved in chronic obstructive pulmonary disease. 2002;34(10):1570–1576.
    1. Gea J, Orozco-Levi M, Barreiro E, Ferrer A, Broquetas J. Structural and functional changes in the skeletal muscles of COPD patients: the “compartments” theory. 2001;56(3):214–224.
    1. Swallow EB, Reyes D, Hopkinson NS, et al. Quadriceps strength predicts mortality in patients with moderate to severe chronic obstructive pulmonary disease. 2007;62(2):115–120.
    1. Vrieze A, de Greef MHG, Wýkstra PJ, Wempe JB. Low bone mineral density in COPD patients related to worse lung function, low weight and decreased fat-free mass. 2007;18(9):1197–1202.
    1. Sin DD, Man JP, Man SFP. The risk of osteoporosis in Caucasian men and women with obstructive airways disease. 2003;114(1):10–14.
    1. Dam T-T, Harrison S, Fink HA, Ramsdell J, Barrett-Connor E. Bone mineral density and fractures in older men with chronic obstructive pulmonary disease or asthma. 2010;21(8):1341–1349.
    1. Nuti R, Siviero P, Maggi S, et al. Vertebral fractures in patients with chronic obstructive pulmonary disease: the EOLO Study. 2009;20(6):989–998.
    1. Ohara T, Hirai T, Muro S, et al. Relationship between pulmonary emphysema and osteoporosis assessed by CT in patients with COPD. 2008;134(6):1244–1249.
    1. Romme EA, Murchison JT, Edwards LD, et al. CT-measured bone attenuation in patients with chronic obstructive pulmonary disease: relation to clinical features and outcomes. 2013;28(6):1369–1377.
    1. Bon J, Fuhrman CR, Weissfeld JL, et al. Radiographic emphysema predicts low bone mineral density in a tobacco-exposed cohort. 2011;183(7):885–890.
    1. Yoon V, Maalouf NM, Sakhaee K. The effects of smoking on bone metabolism. 2012;23(8):2081–2092.
    1. Kok MO, Hoekstra T, Twisk JWR. The longitudinal relation between smoking and muscle strength in healthy adults. 2012;18(2):70–75.
    1. Rapuri PB, Gallagher JC, Smith LM. Smoking is a risk factor for decreased physical performance in elderly women. 2007;62(1):93–100.
    1. Morse CI, Wüst RCI, Jones DA, De Haan A, Degens H. Muscle fatigue resistance during stimulated contractions is reduced in young male smokers. 2007;191(2):123–129.
    1. Barreiro E, Peinado VI, Galdiz JB, et al. Cigarette smoke-induced oxidative stress: a role in chronic obstructive pulmonary disease skeletal muscle dysfunction. 2010;182(4):477–488.
    1. Rom O, Kaisari S, Aizenbud D, Reznick AZ. Identification of possible cigarette smoke constituents responsible for muscle catabolism. 2012;33(3-4):199–208.
    1. Liu Q, Xu W-G, Luo Y, et al. Cigarette smoke-induced skeletal muscle atrophy is associated with up-regulation of USP-19 via p38 and ERK MAPKs. 2011;112(9):2307–2316.
    1. Wüst RCI, Winwood K, Wilks DC, Morse CI, Degens H, Rittweger J. Effects of smoking on tibial and radial bone mass and strength may diminish with age. 2010;95(6):2763–2771.
    1. Ward KD, Klesges RC. A meta-analysis of the effects of cigarette smoking on bone mineral density. 2001;68(5):259–270.
    1. Kanis JA, Johnell O, Oden A, et al. Smoking and fracture risk: a meta-analysis. 2005;16(2):155–162.
    1. Abate M, Vanni D, Pantalone A, Salini V. Cigarette smoking and musculoskeletal disorders. 2013;3(2):63–69.
    1. César-Neto JB, Benatti BB, Manzi FR, Sallum EA, Sallum AW, Nociti FHJ. The influence of cigarette smoke inhalation on bone density. A radiographic study in rats. 2005;19(1):47–51.
    1. Gao S-G, Li K-H, Xu M, et al. Bone turnover in passive smoking female rat: relationships to change in bone mineral density. 2011;12, article 131
    1. Pitta F, Troosters T, Spruit MA, Probst VS, Decramer M, Gosselink R. Characteristics of physical activities in daily life in chronic obstructive pulmonary disease. 2005;171(9):972–977.
    1. Donaire-Gonzalez D, Gimeno-Santos E, Balcells E, et al. Physical activity in COPD patients: patterns and bouts. 2013;42(4):993–1002.
    1. Troosters T, Sciurba F, Battaglia S, et al. Physical inactivity in patients with COPD, a controlled multi-center pilot-study. 2010;104(7):1005–1011.
    1. Watz H, Waschki B, Meyer T, Magnussen H. Physical activity in patients with COPD. 2009;33(2):262–272.
    1. Garcia-Aymerich J, Lange P, Benet M, Schnohr P, Antó JM. Regular physical activity reduces hospital admission and mortality in chronic obstructive pulmonary disease: a population based cohort study. 2006;61(9):772–778.
    1. Seidel D, Cheung A, Suh ES, Raste Y, Atakhorrami M, Spruit MA. Physical inactivity and risk of hospitalisation for chronic obstructive pulmonary disease. 2012;16(8):1015–1019.
    1. Pitta F, Troosters T, Probst VS, Spruit MA, Decramer M, Gosselink R. Physical activity and hospitalization for exacerbation of COPD. 2006;129(3):536–544.
    1. Garcia-Aymerich J, Farrero E, Félez MA, Izquierdo J, Marrades RM, Antó JM. Risk factors of readmission to hospital for a COPD exacerbation: a prospective study. 2003;58(2):100–105.
    1. Shrikrishna D, Patel M, Tanner RJ, et al. Quadriceps wasting and physical inactivity in patients with COPD. 2012;40(5):1115–1122.
    1. Serres I, Gautier V, Varray A, Préfaut C. Impaired skeletal muscle endurance related to physical inactivity and altered lung function in COPD patients. 1998;113(4):900–905.
    1. Walker PP, Burnett A, Flavahan PW, Calverley PMA. Lower limb activity and its determinants in COPD. 2008;63(8):683–689.
    1. Beauchamp MK, Sibley KM, Lakhani B, et al. Impairments in systems underlying control of balance in COPD. 2012;141(6):1496–1503.
    1. Langhammer A, Forsmo S, Syversen U. Long-term therapy in COPD: any evidence of adverse effect on bone? 2009;4:365–380.
    1. Biskobing DM. Copd and osteoporosis. 2002;121(2):609–620.
    1. Schols AMWJ, Buurman WA, Staal-van Den Brekel AJ, Dentener MA, Wouters EFM. Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease. 1996;51(8):819–824.
    1. Singh B, Arora S, Khanna V. Association of severity of COPD with IgE and interleukin-1beta. 2010;73(2):86–87.
    1. Petersen AMW, Penkowa M, Iversen M, et al. Elevated levels of IL-18 in plasma and skeletal muscle in chronic obstructive pulmonary disease. 2007;185(3):161–171.
    1. Gan WQ, Man SFP, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. 2004;59(7):574–580.
    1. de Oca MM, Torres SH, De Sanctis J, Mata A, Hernández N, Tálamo C. Skeletal muscle inflammation and nitric oxide in patients with COPD. 2005;26(3):390–397.
    1. Rabinovich RA, Figueras M, Ardite E, et al. Increased tumour necrosis factor-α plasma levels during moderate-intensity exercise in COPD patients. 2003;21(5):789–794.
    1. Barreiro E, Schols AMWJ, Polkey MI, et al. Cytokine profile in quadriceps muscles of patients with severe COPD. 2008;63(2):100–107.
    1. Koechlin C, Maltais F, Saey D, et al. Hypoxaemia enhances peripheral muscle oxidative stress in chronic obstructive pulmonary disease. 2005;60(10):834–841.
    1. Crul T, Testelmans D, Spruit MA, et al. Gene expression profiling in vastus lateralis muscle during an acute exacerbation of COPD. 2010;25(4-5):491–500.
    1. Barreiro E. Protein carbonylation and muscle function in COPD and other conditions. 2013
    1. Albu A, Fodor D, Poanta L, Man M. Markers of systemic involvement in chronic obstructive pulmonary disease. 2012;50(2):129–134.
    1. Allaire J, Maltais F, Leblanc P, et al. Lipofuscin accumulation in the vastus lateralis muscle in patients with chronic obstructive pulmonary disease. 2002;25(3):383–389.
    1. Cristovao C, Cristovao L, Nogueira F, Bicho M. Evaluation of the oxidant and antioxidant balance in the pathogenesis of chronic obstructive pulmonary disease. 2013;19(2):70–75.
    1. Rahman I, Morrison D, Donaldson K, Macnee W. Systemic oxidative stress in asthma, COPD, and smokers. 1996;154(4):1055–1060.
    1. van Helvoort HAC, Heijdra YF, Dekhuijzen PNR. Systemic immunological response to exercise in patients with chronic obstructive pulmonary disease: what does it mean? 2006;73(2):255–264.
    1. Gosker HR, Bast A, Haenen GRMM, et al. Altered antioxidant status in peripheral skeletal muscle of patients with COPD. 2005;99(1):118–125.
    1. Lawler JM, Song W. Specificity of antioxidant enzyme inhibition in skeletal muscle to reactive nitrogen species donors. 2002;294(5):1093–1100.
    1. Stanojkovic I, Kotur-Stevuljevic J, Milenkovic B, et al. Pulmonary function, oxidative stress and inflammatory markers in severe COPD exacerbation. 2011;105(1):S31–S37.
    1. Renkema TEJ, Schouten JP, Koëter GH, Postma DS. Effects of long-term treatment with corticosteroids in COPD. 1996;109(5):1156–1162.
    1. Williams TJ, O’Hehir RE, Czarny D, Horne M, Bowes G. Acute myopathy in severe acute asthma treated with intravenously administered corticosteroids. 1988;137(2):460–463.
    1. Knox AJ, Mascie-Taylor BH, Muers M. Acute hydrocortisone myopathy in acute severe asthma. 1986;41(5):411–412.
    1. MacFarlane IA, Rosenthal FD. Severe myopathy after status asthmaticus. 1977;2(8038):p. 615.
    1. Decramer M, Lacquet LM, Fagard R, Rogiers P. Corticosteroids contribute to muscle weakness in chronic airflow obstruction. 1994;150(1):11–16.
    1. Decramer M, De Bock V, Dom R. Functional and histologic picture of steroid-induced myopathy in chronic obstructive pulmonary disease. 1996;153(6):1958–1964.
    1. Hopkinson NS, Tennant RC, Dayer MJ, et al. A prospective study of decline in fat free mass and skeletal muscle strength in chronic obstructive pulmonary disease. 2007;8, article 25
    1. Schols AMWJ, Broekhuizen R, Weling-Scheepers CA, Wouters EF. Body composition and mortality in chronic obstructive pulmonary disease. 2005;82(1):53–59.
    1. Van Staa TP, Leufkens HGM, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. 2002;13(10):777–787.
    1. Dubois EF, Röder E, Dekhuijzen PNR, Zwinderman AE, Schweitzer DH. Dual energy x-ray absorptiometry outcomes in male COPD patients after treatment with different glucocorticoid regimens. 2002;121(5):1456–1463.
    1. Johnell O, Pauwels R, Löfdahl C-G, et al. Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbuhaler. 2002;19(6):1058–1063.
    1. Jones A, Fay JK, Burr M, Stone M, Hood K, Roberts G. Inhaled corticosteroid effects on bone metabolism in asthma and mild chronic obstructive pulmonary disease. 2002;(1)CD003537
    1. Halpern MT, Schmier JK, Van Kerkhove MD, Watkins M, Kalberg CJ. Impact of long-term inhaled corticosteroid therapy on bone mineral density: results of a meta-analysis. 2004;92(2):201–267.
    1. Scanlon PD, Connett JE, Wise RA, et al. Loss of bone density with inhaled triamcinoline in lung health study II. 2004;170(12):1302–1309.
    1. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an endocrine society clinical practice guideline. 2010;95(6):2536–2559.
    1. Van Vliet M, Spruit MA, Verleden G, et al. Hypogonadism, quadriceps weakness, and exercise intolerance in chronic obstructive pulmonary disease. 2005;172(9):1105–1111.
    1. Balasubramanian V, Naing S. Hypogonadism in chronic obstructive pulmonary disease: incidence and effects. 2012;18(2):112–117.
    1. Bassil N. Late-Onset Hypogonadism. 2011;95(3):507–523.
    1. Bischoff-Ferrari H. Vitamin D—from essentiality to functionality. 2012;82(5):321–326.
    1. Girgis CM, Clifton-Bligh RJ, Hamrick MW, Holick MF, Gunton JE. The roles of vitamin D in skeletal muscle: form, function, and metabolism. 2013;34(1):33–83.
    1. St-Arnaud R. The direct role of vitamin D on bone homeostasis. 2008;473(2):225–230.
    1. Ceglia L, Harris SS. Vitamin D and its role in skeletal muscle. 2013;92(2):151–162.
    1. Brock K, Huang W-Y, Fraser DR, et al. Low vitamin D status is associated with physical inactivity, obesity and low vitamin D intake in a large US sample of healthy middle-aged men and women. 2010;121(1-2):462–466.
    1. Larrosa M, Gomez A, Casado E, et al. Hypovitaminosis D as a risk factor of hip fracture severity. 2012;23(2):607–614.
    1. Zhang C, Wang C, Liang J, et al. The vitamin D receptor Fok1 polymorphism and bone mineral density in Chinese children. 2008;395(1-2):111–114.
    1. Janssens W, Bouillon R, Claes B, et al. Vitamin D deficiency is highly prevalent in COPD and correlates with variants in the vitamin D-binding gene. 2010;65(3):215–220.
    1. Persson LJ, Aanerud M, Hiemstra PS, Hardie JA, Bakke PS, Eagan TM. Chronic obstructive pulmonary disease is associated with low levels of vitamin D. 2012;7(6)e38934
    1. Kunisaki KM, Niewoehner DE, Connett JE. Vitamin D levels and risk of acute exacerbations of chronic obstructive pulmonary disease: a prospective cohort study. 2012;185(3):286–290.
    1. Puhan MA, Siebeling L, Frei A, Zoller M, Bischoff-Ferrari H, Ter Riet G. No association of 25-hydroxyvitamin D with exacerbations in primary care patients with COPD. 2014;145(1):37–43.
    1. Holick MF. Vitamin D deficiency. 2007;357(3):266–281.
    1. Hopkinson NS, Ka WL, Kehoe A, et al. Vitamin D receptor genotypes influence quadriceps strength in chronic obstructive pulmonary disease. 2008;87(2):385–390.
    1. Jackson AS, Shrikrishna D, Kelly JL, et al. Vitamin D and skeletal muscle strength and endurance in COPD. 2013;41(2):309–316.
    1. Romme EA, Rutten EP, Smeenk FW, Spruit MA, Menheere PP, Wouters EF. Vitamin D status is associated with bone mineral density and functional exercise capacity in patients with chronic obstructive pulmonary disease. 2013;45(1):91–96.
    1. Franco CB, Paz-Filho G, Gomes PE, et al. Chronic obstructive pulmonary disease is associated with osteoporosis and low levels of vitamin D. 2009;20(11):1881–1887.
    1. Engelen MPKJ, Schols AMWJ, Baken WC, Wesseling GJ, Wouters EFM. Nutritional depletion in relation to respiratory and peripheral skeletal muscle function in out-patients with COPD. 1994;7(10):1793–1797.
    1. Vermeeren MAP, Creutzberg EC, Schols AMWJ, et al. Prevalence of nutritional depletion in a large out-patient population of patients with COPD. 2006;100(8):1349–1355.
    1. Itoh M, Tsuji T, Nemoto K, Nakamura H, Aoshiba K. Undernutrition in patients with COPD and its treatment. 2013;5(4):1316–1335.
    1. Vermeeren MAP, Schols AMWJ, Wouters EFM. Effects of an acute exacerbation on nutritional and metabolic profile of patients with COPD. 1997;10(10):2264–2269.
    1. Gupta B, Kant S, Mishra R, Verma S. Nutritional status of chronic obstructive pulmonary disease patients admitted in hospital with acute exacerbation. 2010;2(2):68–74.
    1. Hallin R, Koivisto-Hursti U-K, Lindberg E, Janson C. Nutritional status, dietary energy intake and the risk of exacerbations in patients with chronic obstructive pulmonary disease (COPD) 2006;100(3):561–567.
    1. Zapatero A, Barba R, Ruiz J, et al. Malnutrition and obesity: influence in mortality and readmissions in chronic obstructive pulmonary disease patients. 2013;26(supplement 1):16–22.
    1. Evans WJ, Morley JE, Argilés J, et al. Cachexia: a new definition. 2008;27(6):793–799.
    1. De S. Body mass index among patient with chronic obstructive pulmonary diseases. 2012;56(4):353–358.
    1. Wilson DO, Rogers RM, Wright EC, Anthonisen NR. Body weight in chronic obstructive pulmonary disease: the National Institutes of Health intermittent positive-pressure breathing trial. 1989;139(6):1435–1438.
    1. Mador MJ, Bozkanat E. Skeletal muscle dysfunction in chronic obstructive pulmonary disease. 2001;2(4):216–224.
    1. Schols AMWJ, Slangen J, Volovics L, Wouters EFM. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. 1998;157(6):1791–1797.
    1. Ciric Z, Stankovic I, Pejcic T, Ristic L, Rancic M, Radovic M. Osteoporosis in patients with chronic obstructive pulmonary disease. 2012;66(6):385–387.
    1. Graat-Verboom L, Spruit MA, van den Borne BEEM, et al. Correlates of osteoporosis in chronic obstructive pulmonary disease: an underestimated systemic component. 2009;103(8):1143–1151.
    1. Iqbal F, Michaelson J, Thaler L, Rubin J, Roman J, Nanes MS. Declining bone mass in men with chronic pulmonary disease. Contribution of glucocorticoid treatment, body mass index, and gonadal function. 1999;116(6):1616–1624.
    1. Doherty TJ. Invited review: aging and sarcopenia. 2003;95(4):1717–1727.
    1. Korhonen MT, Cristea A, Alén M, et al. Aging, muscle fiber type, and contractile function in sprint-trained athletes. 2006;101(3):906–917.
    1. Larsson L, Grimby G, Karlsson J. Muscle strength and speed of movement in relation to age and muscle morphology. 1979;46(3):451–456.
    1. Dolbow JD, Dolbow DR, Gorgey AS, Adler RA, Gater DR. The effects of aging and electrical stimulation exercise on bone after spinal cord injury. 2013;4(3):141–153.
    1. Spruit MA, Franssen FM, Rutten EP, Wagers SS, Wouters EF. Age-graded reductions in quadriceps muscle strength and peak aerobic capacity in COPD. 2012;16(2):148–156.
    1. Roig M, Eng JJ, MacIntyre DL, Road JD, Reid WD. Deficits in muscle strength, mass, quality, and mobility in people with chronic obstructive pulmonary disease. 2011;31(2):120–124.
    1. Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. 2012;380(9836):37–43.
    1. Siebeling L, Puhan MA, Muggensturm P, Zoller M, ter Riet G. Characteristics of Dutch and Swiss primary care COPD patients—baseline data of the ICE COLD ERIC study. 2011;3(1):273–283.
    1. Vanfleteren LE, Spruit MA, Groenen M, et al. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. 2013;187(7):728–735.
    1. Remels AH, Gosker HR, Langen RC, Schols AM. The mechanisms of cachexia underlying muscle dysfunction in COPD. 2013;114(9):1253–1262.
    1. Mostert R, Goris A, Weling-Scheepers C, Wouters EFM, Schols AMWJ. Tissue depletion and health related quality of life in patients with chronic obstructive pulmonary disease. 2000;94(9):859–867.
    1. Lainscak M, von Haehling S, Doehner W, et al. Body mass index and prognosis in patients hospitalized with acute exacerbation of chronic obstructive pulmonary disease. 2011;2(2):81–86.
    1. Landbo C, Prescott E, Lange P, Vestbo J, Almdal TP. Prognostic value of nutritional status in chronic obstructive pulmonary disease. 1999;160(6):1856–1861.
    1. Marquis K, Debigaré R, Lacasse Y, et al. Midthigh muscle cross-sectional area is a better predictor of mortality than body mass index in patients with chronic obstructive pulmonary disease. 2002;166(6):809–813.
    1. Prescott E, Almdal T, Mikkelsen KL, Tofteng CL, Vestbo J, Lange P. Prognostic value of weight change in chronic obstructive pulmonary disease: results from the Copenhagen City Heart Study. 2002;20(3):539–544.
    1. Yohannes AM, Baldwin RC, Connolly M. Mortality predictors in disabling chronic obstructive pulmonary disease in old age. 2002;31(2):137–140.
    1. Wagner PD. Possible mechanisms underlying the development of cachexia in COPD. 2008;31(3):492–501.
    1. Guney E, Kisakol G, Ozgen G, Yilmaz C, Yilmaz R, Kabalak T. Effect of weight loss on bone metabolism: comparison of vertical banded gastroplasty and medical intervention. 2003;13(3):383–388.
    1. Elkin SL, Williams L, Moore M, Hodson ME, Rutherford OM. Relationship of skeletal muscle mass, muscle strength and bone mineral density in adults with cystic fibrosis. 2000;99(4):309–314.
    1. Lee N, Radford-Smith GL, Forwood M, Wong J, Taaffe DR. Body composition and muscle strength as predictors of bone mineral density in Crohn’s disease. 2009;27(4):456–463.
    1. Joyce ED, Nolan VG, Ness KK, et al. Association of muscle strength and bone mineral density in adult survivors of childhood acute lymphoblastic leukemia. 2011;92(6):873–879.
    1. Cauley JA, Fullman RL, Stone KL, et al. Factors associated with the lumbar spine and proximal femur bone mineral density in older men. 2005;16(12):1525–1537.
    1. Huuskonen J, Väisänen SB, Kröger H, et al. Determinants of bone mineral density in middle aged men: a population-based study. 2000;11(8):702–708.
    1. Nguyen TV, Center JR, Eisman JA. Osteoporosis in elderly men and women: effects of dietary calcium, physical activity, and body mass index. 2000;15(2):322–331.
    1. Rikkonen T, Sirola J, Salovaara K, et al. Muscle strength and body composition are clinical indicators of osteoporosis. 2012;91(2):131–138.
    1. Rothem DE, Rothem L, Soudry M, Dahan A, Eliakim R. Nicotine modulates bone metabolism-associated gene expression in osteoblast cells. 2009;27(5):555–561.
    1. Tanaka H, Tanabe N, Kawato T, et al. Nicotine affects bone resorption and suppresses the expression of cathepsin K, MMP-9 and vacuolar-type H+-ATPase d2 and actin organization in osteoclasts. 2013;8(3)e59402
    1. Chibalin AV, Heiny JA, Benziane B, et al. Chronic nicotine modifies skeletal muscle Na,K-ATPase activity through its interaction with the nicotinic acetylcholine receptor and phospholemman. 2012;7(3)e33719
    1. Couillard A, Prefaut C. From muscle disuse to myopathy in COPD: potential contribution of oxidative stress. 2005;26(4):703–719.
    1. Koechlin C, Couillard A, Simar D, et al. Does oxidative stress alter quadriceps endurance in chronic obstructive pulmonary disease? 2004;169(9):1022–1027.
    1. MacNee W, Tuder RM. New paradigms in the pathogenesis of chronic obstructive pulmonary disease I. 2009;6(6):527–531.
    1. Bolton CE, Stone MD, Edwards PH, Duckers JM, Evans WD, Shale DJ. Circulating matrix metalloproteinase-9 and osteoporosis in patients with chronic obstructive pulmonary disease. 2009;6(2):81–87.
    1. Yanbaeva DG, Dentener MA, Creutzberg EC, Wesseling G, Wouters EFM. Systemic effects of smoking. 2007;131(5):1557–1566.
    1. Broekhuizen R, Wouters EFM, Creutzberg EC, Schols AMWJ. Raised CRP levels mark metabolic and functional impairment in advanced COPD. 2006;61(1):17–22.
    1. Yende S, Waterer GW, Tolley EA, et al. Inflammatory markers are associated with ventilatory limitation and muscle dysfunction in obstructive lung disease in well functioning elderly subjects. 2006;61(1):10–16.
    1. Debigaré R, Marquis K, Côté CH, et al. Catabolic/anabolic balance and muscle wasting in patients with COPD. 2003;124(1):83–89.
    1. Gaki E, Kontogianni K, Papaioannou AI, et al. Associations between BODE index and systemic inflammatory biomarkers in COPD. 2011;8(6):408–413.
    1. Spate U, Schulze PC. Proinflammatory cytokines and skeletal muscle. 2004;7(3):265–269.
    1. Glass DJ. Skeletal muscle hypertrophy and atrophy signaling pathways. 2005;37(10):1974–1984.
    1. Manolagas SC. The role of IL-6 type cytokines and their receptors in bone a. 1998;840:194–204.
    1. Bai P, Sun Y, Jin J, et al. Disturbance of the OPG/RANK/RANKL pathway and systemic inflammation in COPD patients with emphysema and osteoporosis. 2011;12, article 157
    1. Liang B, Feng Y. The association of low bone mineral density with systemic inflammation in clinically stable COPD. 2011:1–6.
    1. Rittayamai N, Chuaychoo B, Sriwijitkamol A. Prevalence of osteoporosis and osteopenia in Thai COPD patients. 2012;95(8):1021–1027.
    1. Lacativa PG, Farias ML. Osteoporosis and inflammation. 2010;54(2):123–132.
    1. Larson NI, Story M, Perry CL, Neumark-Sztainer D, Hannan PJ. Are diet and physical activity patterns related to cigarette smoking in adolescents? Findings from Project EAT. 2007;4(3):p. A51.
    1. Takata S, Yasui N. Disuse osteoporosis. 2001;48(3-4):147–156.
    1. Powers SK, Smuder AJ, Judge AR. Oxidative stress and disuse muscle atrophy: cause or consequence? 2012;15(3):240–245.
    1. Urban RJ, Bodenburg YH, Gilkison C, et al. Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis. 1995;269(5):E820–E826.
    1. Frederiksen L, Højlund K, Hougaard DM, Brixen K, Andersen M. Testosterone therapy increased muscle mass and lipid oxidation in aging men. 2012;34(1):145–156.
    1. Sih R, Morley JE, Kaiser FE, Perry HM, III, Patrick P, Ross C. Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. 1997;82(6):1661–1667.
    1. Storer TW, Woodhouse L, Magliano L, et al. Changes in muscle mass, muscle strength, and power but not physical function are related to testosterone dose in healthy older men. 2008;56(11):1991–1999.
    1. Snyder PJ, Peachey H, Berlin JA, et al. Effects of testosterone replacement in hypogonadal men. 2000;85(8):2670–2677.
    1. Tracz MJ, Sideras K, Boloña ER, et al. Testosterone use in men and its effects on bone health. A systematic review and meta-analysis of randomized placebo-controlled trials. 2006;91(6):2011–2016.
    1. Anderson FH, Francis RM, Peaston RT, Wastell HJ. Androgen supplementation in eugonadal men with osteoporosis: effects of six months’ treatment on markers of bone formation and resorption. 1997;12(3):472–478.
    1. Wang C, Swerdloff RS, Iranmanesh A, et al. Effects of transdermal testosterone gel on bone turnover markers and bone mineral density in hypogonadal men. 2001;54(6):739–750.
    1. Katznelson L, Finkelstein JS, Schoenfeld DA, Rosenthal DI, Anderson EJ, Klibanski A. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. 1996;81(12):4358–4365.
    1. Girasole G, Jilka RL, Passeri G, et al. 17β-Estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: a potential mechanism for the antiosteoporotic effect of estrogens. 1992;89(3):883–891.
    1. Atlantis E, Fahey P, Cochrane B, Wittert G, Smith S. Endogenous testosterone level and testosterone supplementation therapy in chronic obstructive pulmonary disease (COPD): a systematic review and meta-analysis. 2013;3(8)e003127
    1. Velema MS, Kwa BHB, De Ronde W. Should androgenic anabolic steroids be considered in the treatment regime of selected chronic obstructive pulmonary disease patients? 2012;18(2):118–124.
    1. Ferreira IM, Verreschi IT, Nery LE, et al. The influence of 6 months of oral anabolic steroids on body mass and respiratory muscles in undernourished COPD patients. 1998;114(1):19–28.
    1. Svartberg J, Aaseboø U, Hjalmarsen A, Sundsfjord J, Jorde R. Testosterone treatment improves body composition and sexual function in men with COPD, in a 6-month randomized controlled trial. 2004;98(9):906–913.
    1. Fernández-Balsells MM, Murad MH, Lane M, et al. Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. 2010;95(6):2560–2575.
    1. Drewa T, Chłosta P. Testosterone supplementation and prostate cancer, controversies still exist. 2010;67(5):543–546.
    1. Bischoff-Ferrari HA. Relevance of vitamin D in muscle health. 2012;13(1):71–77.
    1. Bischoff-Ferrari HA, Conzelmann M, Stähelin HB, et al. Is fall prevention by vitamin D mediated by a change in postural or dynamic balance? 2006;17(5):656–663.
    1. Chapuy MC, Arlot ME, Duboeuf F, et al. Vitamin D3 and calcium to prevent hip fractures in elderly women. 1992;327(23):1637–1642.
    1. Bischoff HA, Stähelin HB, Dick W, et al. Effects of vitamin D and calcium supplementation on falls: a randomized controlled trial. 2003;18(2):343–351.
    1. Pfeifer M, Begerow B, Minne HW, Suppan K, Fahrleitner-Pammer A, Dobnig H. Effects of a long-term vitamin D and calcium supplementation on falls and parameters of muscle function in community-dwelling older individuals. 2009;20(2):315–322.
    1. Bunout D, Barrera G, Leiva L, et al. Effects of vitamin D supplementation and exercise training on physical performance in Chilean vitamin D deficient elderly subjects. 2006;41(8):746–752.
    1. Bjerk SM, Edgington BD, Rector TS, Kunisaki KM. Supplemental vitamin D and physical performance in COPD: a pilot randomized trial. 2013;8:97–104.
    1. Hornikx M, Van RH, Lehouck A, et al. Vitamin D supplementation during rehabilitation in COPD: a secondary analysis of a randomized trial. 2012;13:p. 84.
    1. Lehouck A, Mathieu C, Carremans C, et al. High doses of vitamin D to reduce exacerbations in chronic obstructive pulmonary disease: a randomized trial. 2012;156(2):105–120.
    1. Nici L, Donner C, Wouters E, et al. American thoracic society/European respiratory society statement on pulmonary rehabilitation. 2006;173(12):1390–1413.
    1. O’Shea SD, Taylor NF, Paratz J. Peripheral muscle strength training in COPD: a systematic review. 2004;126(3):903–914.
    1. Donaldson AV, Maddocks M, Martolini D, Polkey MI, Man WD. Muscle function in COPD: a complex interplay. 2012;7:523–535.
    1. Lacasse Y, Goldstein R, Lasserson TJ, Martin S. Pulmonary rehabilitation for chronic obstructive pulmonary disease. 2006;(4)CD003793
    1. Spruit MA, Gosselink R, Troosters T, De Paepe K, Decramer M. Resistance versus endurance training in patients with COPD and peripheral muscle weakness. 2002;19(6):1072–1078.
    1. Troosters T, Gosselink R, Decramer M. Short- and long-term effects of outpatient rehabilitation in patients with chronic obstructive pulmonary disease: a randomized trial. 2000;109(3):207–212.
    1. Casaburi R, Bhasin S, Cosentino L, et al. Effects of testosterone and resistance training in men with chronic obstructive pulmonary disease. 2004;170(8):870–878.
    1. Creutzberg EC, Wouters EFM, Mostert R, Pluymers RJ, Schols AMWJ. A role for anabolic steroids in the rehabilitation of patients with COPD? A double-blind, placebo-controlled, randomized trial. 2003;124(5):1733–1742.
    1. Vogiatzis I, Terzis G, Nanas S, et al. Skeletal muscle adaptations to interval training in patients with advanced COPD. 2005;128(6):3838–3845.
    1. Vogiatzis I, Stratakos G, Simoes DCM, et al. Effects of rehabilitative exercise on peripheral muscle TNFα, IL-6, IGF-I and MyoD expression in patients with COPD. 2007;62(11):950–956.
    1. Vogiatzis I, Terzis G, Stratakos G, et al. Effect of pulmonary rehabilitation on peripheral muscle fiber remodeling in patients with COPD in GOLD stages II to IV. 2011;140(3):744–752.
    1. Whittom F, Jobin J, Simard P-M, et al. Histochemical and morphological characteristics of the vastus lateralis muscle in patients with chronic obstructive pulmonary disease. 1998;30(10):1467–1474.
    1. Green HJ, Burnett ME, D’Arsigny CL, O’Donnell DE, Ouyang J, Webb KA. Altered metabolic and transporter characteristics of vastus lateralis in chronic obstructive pulmonary disease. 2008;105(3):879–886.
    1. Troosters T, Probst VS, Crul T, et al. Resistance training prevents deterioration in quadriceps muscle function during acute exacerbations of chronic obstructive pulmonary disease. 2010;181(10):1072–1077.
    1. Puhan MA, Gimeno-Santos E, Scharplatz M, Troosters T, Walters EH, Steurer J. Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. 2011;(10)CD005305
    1. Menkes A, Mazel S, Redmond RA, et al. Strength training increases regional bone mineral density and bone remodeling in middle-aged and older men. 1993;74(5):2478–2484.
    1. Borer KT. Physical activity in the prevention and amelioration of osteoporosis in women: interaction of mechanical, hormonal and dietary factors. 2005;35(9):779–830.
    1. Eleftheriou KI, Rawal JS, James LE, et al. Bone structure and geometry in young men: the influence of smoking, alcohol intake and physical activity. 2013;52(1):17–26.
    1. Lorentzon M, Mellström D, Ohlsson C. Association of amount of physical activity with cortical bone size and trabecular volumetric BMD in young adult men: the GOOD study. 2005;20(11):1936–1943.
    1. Lotshaw AM, Thompson M, Sadowsky HS, Hart MK, Millard MW. Quality of life and physical performance in land- and water-based pulmonary rehabilitation. 2007;27(4):247–251.
    1. McNamara RJ, McKeough ZJ, McKenzie DK, Alison JA. Water-based exercise in COPD with physical comorbidities: a randomised controlled trial. 2013;41(6):1284–1291.
    1. Bergamin M, Ermolao A, Tolomio S, Berton L, Sergi G, Zaccaria M. Water- versus land-based exercise in elderly subjects: effects on physical performance and body composition. 2013;8:1109–1117.
    1. Devereux K, Robertson D, Briffa NK. Effects of a water-based program on women 65 years and over: a randomised controlled trial. 2005;51(2):102–108.
    1. Tsukahara N, Toda A, Goto J, Ezawa I. Cross-sectional and longitudinal studies on the effect of water exercise in controlling bone loss in Japanese postmenopausal women. 1994;40(1):37–47.
    1. Sillen MJH, Wouters EFM, Franssen FME, Meijer K, Stakenborg KHP, Spruit MA. Oxygen uptake, ventilation, and symptoms during low-frequency versus high-frequency NMES in COPD: a pilot study. 2011;189(1):21–26.
    1. Neder JA, Sword D, Ward SA, Mackay E, Cochrane LM, Clark CJ. Home based neuromuscular electrical stimulation as a new rehabilitative strategy for severely disabled patients with chronic obstructive pulmonary disease (COPD) 2002;57(4):333–337.
    1. Bourjeily-Habr G, Rochester CL, Palermo F, Snyder P, Mohsenin V. Randomised controlled trial of transcutaneous electrical muscle stimulation of the lower extremities in patients with chronic obstructive pulmonary disease. 2002;57(12):1045–1049.
    1. Vivodtzev I, Pépin J-L, Vottero G, et al. Improvement in quadriceps strenght and dyspnea in daily tasks after 1 month of electrical stimulation in severely deconditioned and malnourished COPD. 2006;129(6):1540–1548.
    1. Zanotti E, Felicetti G, Maini M, Fracchia C. Peripheral muscle strength training in bed-bound patients with COPD receiving mechanical ventilation: effect of electrical stimulation. 2003;124(1):292–296.
    1. Dal Corso S, Nápolis L, Malaguti C, et al. Skeletal muscle structure and function in response to electrical stimulation in moderately impaired COPD patients. 2007;101(6):1236–1243.
    1. Vivodtzev I, Debigaré R, Gagnon P, et al. Functional and muscular effects of neuromuscular electrical stimulation in patients with severe COPD: a randomized clinical trial. 2012;141(3):716–725.
    1. Abdellaoui A, Préfaut C, Gouzi F, et al. Skeletal muscle effects of electrostimulation after COPD exacerbation: a pilot study. 2011;38(4):781–788.
    1. Bosco C, Cardinale M, Tsarpela O. Influence of vibration on mechanical power and electromyogram activity in human arm flexor muscles. 1999;79(4):306–311.
    1. Delecluse C, Roelants M, Verschueren S. Strength increase after whole-body vibration compared with resistance training. 2003;35(6):1033–1041.
    1. Rittweger J, Mutschelknauss M, Felsenberg D. Acute changes in neuromuscular excitability after exhaustive whole body vibration exercise as compared to exhaustion by squatting exercise. 2003;23(2):81–86.
    1. Torvinen S, Kannus P, Sievänen H, et al. Effect of 8-month vertical whole body vibration on bone, muscle performance, and body balance: a randomized controlled study. 2003;18(5):876–884.
    1. de Zepetnek JOT, Giangregorio LM, Craven BC. Whole-body vibration as potential intervention for people with low bone mineral density and osteoporosis: a review. 2009;46(4):529–542.
    1. Pleguezuelos E, Perez ME, Guirao L, et al. Effects of whole body vibration training in patients with severe chronic obstructive pulmonary disease. 2013;18(6):1028–1034.
    1. Gloeckl R, Heinzelmann I, Baeuerle S, et al. Effects of whole body vibration in patients with chronic obstructive pulmonary disease—a randomized controlled trial. 2012;106(1):75–83.
    1. Planas M, Álvarez J, García-Peris PA, et al. Nutritional support and quality of life in stable chronic obstructive pulmonary disease (COPD) patients. 2005;24(3):433–441.
    1. Ferreira IM, Brooks D, Lacasse Y, Goldstein RS. Nutritional support for individuals with COPD: a meta-analysis. 2000;117(3):672–678.
    1. Ferreira IM, Brooks D, Lacasse Y, Goldstein RS, White J. Nutritional supplementation for stable chronic obstructive pulmonary disease. 2005;(2)CD000998
    1. Efthimiou J, Fleming J, Gomes C, Spiro SG. The effects of supplementary oral nutrition in poorly nourished patients with chronic obstructive pulmonary disease. 1988;137(5):1075–1082.
    1. Ferreira IM, Brooks D, Lacasse Y, Goldstein RS. Nutritional supplementation in stable chronic obstructive pulmonary disease. 2000;(3)CD000998
    1. Weekes CE, Emery PW, Elia M. Dietary counselling and food fortification in stable copd: a randomised trial. 2009;64(4):326–331.
    1. Vermeeren MAP, Wouters EFM, Geraerts-Keeris AJW, Schols AMWJ. Nutritional support in patients with chronic obstructive pulmonary disease during hospitalization for an acute exacerbation; a randomized controlled feasibility trial. 2004;23(5):1184–1192.
    1. Creutzberg EC, Wouters EFM, Mostert R, Weling-Scheepers CAPM, Schols AMWJ. Efficacy of nutritional supplementation therapy in depleted patients with chronic obstructive pulmonary disease. 2003;19(2):120–127.
    1. Beauchamp MK, Hill K, Goldstein RS, Janaudis-Ferreira T, Brooks D. Impairments in balance discriminate fallers from non-fallers in COPD. 2009;103(12):1885–1891.
    1. Roig M, Eng JJ, MacIntyre DL, et al. Falls in people with chronic obstructive pulmonary disease: an observational cohort study. 2011;105(3):461–469.
    1. Henderson NK, White CP, Eisman JA. The roles of exercise and fall risk reduction in the prevention of osteoporosis. 1998;27(2):369–387.
    1. Sinaki M. Exercise for patients with osteoporosis: management of vertebral compression fractures and trunk strengthening for fall prevention. 2012;4(11):882–888.
    1. Suominen H. Muscle training for bone strength. 2006;18(2):85–93.
    1. Englund U, Nordström P, Nilsson J, et al. Physical activity in middle-aged women and hip fracture risk: the UFO study. 2011;22(2):499–505.
    1. Beauchamp MK, Janaudis-Ferreira T, Parreira V, et al. A randomized controlled trial of balance training during pulmonary rehabilitation for individuals with COPD. 2013;144(6):1803–1810.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi